Pseudomonas aeruginosa
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | - |
- | - | - | - |
Azithromycin | - |
- | - |
- | - |
Aztreonam | 80 |
86 | 86 |
85 | 86 |
Cefazolin | - |
- | -
- |
- |
|
Cefepime | 91 |
94 | 95
96 |
95 |
|
Ceftazidime | 95 |
97 | 98 |
96 | 96 |
Ceftriaxone | 32 |
37 | 17 |
- | - |
Cefuroxime | - |
- | -
- |
- |
|
Ciprofloxacin | 82 |
80 | 86 |
87 | 90 |
Clarithromycin | - |
- | - |
- | - |
Clindamycin | - |
- | - |
- | - |
Doxycycline | - |
- | - |
- | - |
Erythromycin | - |
- | - |
- | - |
Gentamicin | 82 |
93 | 88 |
81 | 90 |
Imipenem | 93 |
96 | 96 |
93 | 91 |
Levofloxacin | 81 | 79 | 84 | 85 | 89 |
Meropenem | + | 98 | 99 | 99 | 98 |
Moxifloxacin | + | + | + | + | + |
Nitrofurantoin | - | - | - | - | - |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | - | - | - | - | - |
Piperacillin | 97 | 99 | 100 | + | + |
Piperacillin/tazo | 98 | 99 | 100 | 99 | 99 |
Ticarcillin/Clav | + | + | + | + | + |
Tobramycin | 97 | 99 | 99 | 99 | 99 |
TMP/SMX | - | - | - | - | - |
Unasyn/Aug | - | - | - | - | - |
Vancomycin | - | - | - | - | - |
# Tested | 472 | 535 | 394 | 454 | 494 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections